LYNPARZA™ (Olaparib) granted Breakthrough Therapy Designation by US FDA for
treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant
AstraZeneca today announced that the US Food and Drug Administration (FDA) has
granted Breakthrough Therapy designation (BTD) for the oral poly ADP-ribose
polymerase (PARP) inhibitor Lynparza™ (olaparib), for the monotherapy treatment
of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer
(mCRPC) in patients who have received a prior taxane-based chemotherapy and at
least one newer hormonal agent (abiraterone or enzalutamide).
The FDA criteria for BTD require preliminary clinical evidence that demonstrates
a drug may have substantial improvement on at least one clinically significant
endpoint over available therapy. The decision to assign a BTD for Lynparza is
based on the results of the TOPARP-A Phase II trial, which found that Lynparza
(olaparib) monotherapy in mCPRPC may offer substantial improvement over
available therapies for the treatment of the biomarker-selected population with
this serious and life-threatening condition. The TOPARP-A Phase II trial was
presented at AACR 2015 and published in the New England Journal of Medicine in
October 2015[i]. It showed that men with prostate cancer with defective DNA
damage repair mechanisms responded to Lynparza (olaparib).
The Breakthrough Therapy designation for Lynparza in this patient population
means the FDA will expedite review of submission data within 60 days of receipt.
Antoine Yver, Head of Oncology, Global Medicines Development at AstraZeneca,
said: “More than 27,000 men died of prostate cancer last year in the US alone.
The Breakthrough Therapy designation for Lynparza is encouraging news for
patients, and their families, as there are currently very limited treatment
options for metastatic Castration Resistant Prostate Cancer. We will work
closely with the FDA to introduce Lynparza as a new treatment option as soon as
Once prostate cancer has progressed to mCPRPC, treatment focuses on extending
life, delaying disease progression, and improving symptoms and quality of life.
Overall survival time for patients treated with chemotherapy and newer hormonal
agents is 10 months[ii]. There are also no approved therapies for third line and
above (3L+) mCRPC patients, and no targeted therapies are available for mCRPC
patients with somatic or germline mutations in BRCA1, BRCA2 or ATM.
Lynparza (olaparib) is an innovative, first-in-class oral poly ADP-ribose
polymerase (PARP) inhibitor that exploits tumour DNA repair pathway deficiencies
to preferentially kill cancer cells. This mode of action gives olaparib the
potential for activity in a range of tumour types with DNA repair deficiencies.
Lynparza has been approved by regulatory authorities in 40 countries for the
maintenance treatment of women with BRCA-mutated ovarian cancer. AstraZeneca is
investigating the potential of olaparib in other PARP dependent tumours. Phase
III studies in gastric cancer, pancreatic cancer and adjuvant and metastatic
BRCAm breast cancers are underway, with further studies planned.
NOTES TO EDITORS
About prostate cancer
In 2015, 27,540 US men died of prostate cancer[iii]. Based on the Global Burden
of Disease Cancer Collaboration, there were 1.4 million incidents of prostate
cancer and 293,000 deaths worldwide for the year 2013. Prostate cancer caused
4.8 million disability-adjusted life-years globally in 2013, with 57% occurring
in developed countries and 43% occurring in developing countries[iv].
About AstraZeneca in Oncology
Oncology is a therapy area in which AstraZeneca has deep-rooted heritage. It
will be potentially transformational for the company’s future, becoming the
sixth growth platform. Our vision is to help patients by redefining the cancer
treatment paradigm and one day eliminate cancer as a cause of death. By 2020, we
are aiming to bring at least six new cancer medicines to patients.
Our broad pipeline of next-generation medicines is focused on four main disease
areas – lung, ovarian, breast and haematological cancers. These are being
targeted through four key platforms – immuno-oncology, the genetic drivers of
cancer and resistance, DNA damage repair and antibody drug conjugates – with a
strong focus on combinations. Our recently announced investment in Acerta Pharma
also adds the potentially transformational BTK inhibitor class of treatments to
our portfolio, subject to closure in the first quarter of 2016, strengthening
further our focus on targeted therapies.
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main therapy areas –
respiratory, inflammation, autoimmune disease (RIA), cardiovascular and
metabolic disease (CVMD) and oncology – as well as in infection and
neuroscience. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com
Esra Erkal-Paler UK/Global +44 20 7604 8030
Neil Burrows UK/Global +44 20 7604 8032
Vanessa Rhodes UK/Global +44 20 7604 8037
Karen Birmingham UK/Global +44 20 7604 8120
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Thomas Kudsk Larsen Oncology +44 7818 524185
Eugenia Litz RIA +44 7884 735627
Nick Stone CVMD +44 7717 618834
Craig Marks Finance +44 7881 615764
Christer Gruvris Consensus Forecasts +44 7827 836825
Lindsey Trickett Oncology, ING +1 240 543 7970
Mitch Chan Oncology +1 240 477 3771
Dial / Toll-Free +1 866 381 7277
Key: RIA – Respiratory, Inflammation and Autoimmunity, CVMD – Cardiovascular and
ING – Infection, Neuroscience and Gastrointestinal
28 January 2016
[i]Mateo J, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate
[ii] Smith MR, DeBono JS, Sternberg CN, Le Moulec S, Oudard S, De Giorgi U et
al. Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in
metastatic castration-resistant prostate cancer (mCRPC) patients (pts)
previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide
(E).ASCO GU 2015. J Clin Oncol 2015;33(7):abstr 139.
[iii] National Cancer Institute 2015. http://www.cancer.gov/types/common-cancers
accessed September 2015
[iv]Global Burden of Cancer Coalition. The Global Burden of Cancer 2013. JAMA
Oncol. 2015;1(4):505-527. doi:10.1001/jamaoncol.2015.0735.